These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18463389)

  • 1. More on subgroup analyses in clinical trials.
    Pocock SJ; Lubsen J
    N Engl J Med; 2008 May; 358(19):2076; author reply 2076-7. PubMed ID: 18463389
    [No Abstract]   [Full Text] [Related]  

  • 2. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistics in medicine--reporting of subgroup analyses in clinical trials.
    Wang R; Lagakos SW; Ware JH; Hunter DJ; Drazen JM
    N Engl J Med; 2007 Nov; 357(21):2189-94. PubMed ID: 18032770
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to expression of concern regarding VIGOR study.
    Reicin A; Shapiro D
    N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16544387
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons learned after the withdrawal of rofecoxib.
    Giaquinta D
    Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 7. Merck VIOXX "warning" is questioned.
    Allen TS; Henderson JH
    Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
    [No Abstract]   [Full Text] [Related]  

  • 8. NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial.
    Dobson R
    BMJ; 2006 Jul; 333(7559):116. PubMed ID: 16840463
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to expression of concern regarding VIGOR study.
    Bombardier C; Laine L; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ; Weaver A
    N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16495387
    [No Abstract]   [Full Text] [Related]  

  • 10. A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event.
    Whitstock MT; Pearce CM; Ridout SC; Eckermann EJ
    Aust N Z J Public Health; 2010 Aug; 34(4):431-2. PubMed ID: 20649787
    [No Abstract]   [Full Text] [Related]  

  • 11. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 12. [How many harmed by rofecoxib in Germany?].
    Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
    Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rofecoxib increases myocardial infarction risk in seniors].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032
    [No Abstract]   [Full Text] [Related]  

  • 14. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Mühlbauer B; Timm J
    Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
    [No Abstract]   [Full Text] [Related]  

  • 15. Subgroup analyses in clinical trials.
    Proestel S
    N Engl J Med; 2008 Mar; 358(11):1199; author reply 1199-200. PubMed ID: 18337613
    [No Abstract]   [Full Text] [Related]  

  • 16. Time-to-event analyses for long-term treatments--the APPROVe trial.
    Lagakos SW
    N Engl J Med; 2006 Jul; 355(2):113-7. PubMed ID: 16801354
    [No Abstract]   [Full Text] [Related]  

  • 17. Subgroup analyses in clinical trials.
    Kent D; Hayward R
    N Engl J Med; 2008 Mar; 358(11):1199; author reply 1199-200. PubMed ID: 18340666
    [No Abstract]   [Full Text] [Related]  

  • 18. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 19. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
    Brune K; Zacher J
    MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.